A rating of 77 puts Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) near the top of the Healthcare sector according to InvestorsObserver.
Bio-Rad Laboratories, Inc. Class A Common Stock's score of 77 means that it ranks higher than 77% of stocks in the sector. In addition, its overall score of 65 ranks it higher than 65% of all stocks.
BIO has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on BIO!
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style.
Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Bio-Rad Laboratories, Inc. Class A Common Stock Stock Today?
Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock is trading at $726.93 as of 2:21 PM on Monday, Oct 18, a rise of $4.97, or 0.69% from the previous closing price of $721.96. The stock has traded between $715.15 and $728.05 so far today. Volume today is low. So far 32,655 shares have traded compared to average volume of 135,964 shares.
Click Here to get the full Stock Report for Bio-Rad Laboratories, Inc. Class A Common Stock stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
